Global Drugs of Abuse (DOA) Testing Market Size, Trends and Growth Opportunity, By Product (Consumables, Analyzers, Equipment), By Sample Type (Urine, Saliva, Hair, Others), By Application (Pain Management, Criminal Justice, Workplace Screening), By End Users (Hospitals, Laboratories, Workplace, At Home, Others), By Region and forecast till 2027.
Global Drugs of Abuse (DOA) Testing Market
Global Drugs of Abuse (DOA) Testing Market was valued at USD 7.2 Bn in 2021 and is slated to reach at USD 8.3 Bn by 2027 at a CAGR of 1.98% from 2022-2027.
Drug of Abuse testing is a clinical screening method used to find one or more unlawful substances, such as a drug, chemical, or plant product the patient is addicted to. Utilizing the patient's urine, saliva, blood, hair, or sweat, this clinical screening procedure.
Market Drivers
DoA testing will be highly demanded as new and illegal drugs are produced, consumed, and traded at an accelerated rate, spurring business expansion. In 2015, there were 255 million users of illicit drugs worldwide, according to the 2017 World Drug Report of the UN Office on Drugs and Crime. This will make DOA testing necessary, driving the market forward. The government's actions to promote DOA awareness and boost corporate compliance for DOA testing will aid in the expansion of the market as a whole. The sector will expand as a result of the strong demand for goods with more specificity and sensitivity to designer pharmaceuticals. Leading competitors in the DoA testing market are increasing their product range with novel substances for DoA testing in order to maintain their competency and market dominance. Shimadzu Corporation, for example, introduced its Smart Forensic Database Ver. 2 in February 2018, including features for analysing forensic toxicological compounds involved in DoA in biological samples utilising Gas Chromatograph-Mass Spectrometry. Similarly, Thermo Fisher Scientific Inc. upgraded its library for the Thermo Scientific TruNarc handheld narcotics analyzer in November 2017. The upgrade included 45 new chemicals to the handheld narcotics analyzer, including 14 new types of fentanyl, and it can now detect Carfentanil.
Market Restraints
The inadequacy of these testing products to detect minute levels of particular medications is predicted to stymie industry expansion. The alteration of legislation to legalise the use of recreational drugs/illicit substances is likely to challenge the drugs of abuse (DOA) testing market during the forecast period.
Market Segmentation
Global Drugs of Abuse (DOA) Testing Market is segmented into Product, Sample Type, Application, End-Users. By Product such as Consumables, Rapid test kits, Assay kits, Reagents, Others, Blood, Breath, Analyzers, Equipment, Immunoassay analyzers, Chromatography instruments, Breath analyzers. By Sample Type such as Urine, Saliva, Hair, Others. By Application such as Pain Management, Criminal Justice, Workplace Screening. By End-Users such as Hospitals, Laboratories, Workplace, At Home, Others.
Regional Analysis
Global Drugs of Abuse (DOA) Testing Market is segmented into five regions North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America dominates the drugs of abuse (DOA) testing industry due to the region's high availability of illegal substances, rising drug trafficking, and increased workplace drug testing. Asia-Pacific is predicted to develop at the fastest
rate over the projection period, owing to the region's rising usage of illegal substances and increased corporate adherence to workplace drug testing.
Key Players
This report includes a list of numerous Key Players, namely Takeda Pharmaceutical Company Limited (Japan), F. Hoffmann-La Roche Ltd (Switzerland), Abbott (U.S.), Medtronic (Ireland), Johnson & Johnson Services, Inc. (U.S.), GSK Plc. (U.K.), Bayer AG (Germany), Zimmer Biomet (U.S.), Stryker Corporation (U.S.), Homology Medicines, Inc (U.S.).
Market Taxonomy
By Product
•        Consumables
•        Rapid test kits
•        Assay kits
•        Reagents
•        Others
•        Blood
•        Breath
•        Analyzers
•        Equipment
•        Immunoassay analyzers
•        Chromatography instruments
•        Breath analyzers
 By Sample Type
•        Urine
•        Saliva
•        Hair
•        Others 
By Application
•        Pain Management
•        Criminal Justice
•        Workplace Screening
By End Users
•        Hospitals
•        Laboratories
•        Workplace
•        At Home
•        Others
By Region
•        North America
•        Latin America
•        Europe
•        Asia Pacific
•        Middle East & Africa.

Global Drugs of Abuse (DOA) Testing Market TOC:
1 Introduction        
1.1 Objective of the Study
1.2 Market definition
1.3 Market Scope
2 Research Methodology
2.1 Data Mining
2.2 Validation
2.3 Primary Interviews
2.4 List of Data Sources
3 Executive Summary
4 Global Drugs of Abuse (DOA) Testing Market Outlook
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
5 Global Drugs of Abuse (DOA) Testing Market, By Product  
5.1 Y-o-Y Growth Comparison, By Product
5.2 Global Drugs of Abuse (DOA) Testing Market Share Analysis, By Product
5.3 Global Drugs of Abuse (DOA) Testing Market Size and Forecast, By Product
5.3.1 Consumables
5.3.2 Rapid test kits
5.3.3 Assay kits
5.3.4 Reagents
5.3.5 Others
5.3.6 Blood
5.3.7 Breath
5.3.8 Analyzers
5.3.9 Equipment
5.3.10 Immunoassay analyzers
5.3.11 Chromatography instruments
5.3.12 Breath analyzers
6 Global Drugs of Abuse (DOA) Testing Market, By Application
6.1 Y-o-Y Growth Comparison, By Application 
6.2 Global Drugs of Abuse (DOA) Testing Market Share Analysis, By Application 
6.3 Global Drugs of Abuse (DOA) Testing Market Size and Forecast, By Application 
6.3.1 Pain Management
6.3.2 Criminal Justice
6.3.3 Workplace Screening
7 Global Drugs of Abuse (DOA) Testing Market, By Sample Type
7.1 Y-o-Y Growth Comparison, By Sample Type
7.2 Global Drugs of Abuse (DOA) Testing Market Share Analysis, By Sample Type
7.3 Global Drugs of Abuse (DOA) Testing Market Size and Forecast, By Sample Type
7.3.1 Urine
7.3.2 Saliva
7.3.3 Hair
7.3.4 Others
8 Global Drugs of Abuse (DOA) Testing Market, By End Users
8.1 Y-o-Y Growth Comparison, By End Users
8.2 Global Drugs of Abuse (DOA) Testing Market Share Analysis, By End Users
8.3 Global Drugs of Abuse (DOA) Testing Market Size and Forecast, By End Users
8.3.1 Hospitals
8.3.2 Laboratories
8.3.3 Workplace
8.3.4 At Home
8.3.5 Others
9 Global Drugs of Abuse (DOA) Testing Market, By Region
9.1 Global Drugs of Abuse (DOA) Testing Market Share Analysis, By Region
9.2 Global Drugs of Abuse (DOA) Testing Market Share Analysis, By Region
9.3 Global Drugs of Abuse (DOA) Testing Market Size and Forecast, By Region
10 North America Drugs of Abuse (DOA) Testing Market Analysis and Forecast (2022-2027)
10.1 Introduction
10.2 North America Drugs of Abuse (DOA) Testing Market Share Analysis, By Product
10.3 North America Drugs of Abuse (DOA) Testing Market Size and Forecast, By Sample Type
10.4 North America Drugs of Abuse (DOA) Testing Market Size and Forecast, By Application
10.5 North America Drugs of Abuse (DOA) Testing Market Size and Forecast, By End-User
10.6 North America Drugs of Abuse (DOA) Testing Market Size and Forecast, By Country
10.6.1 U.S.
10.6.2 Canada
10.6.3 Mexico
11 Europe Drugs of Abuse (DOA) Testing Market Analysis and Forecast (2022-2027)
11.1 Introduction
11.2 Europe Drugs of Abuse (DOA) Testing Market Share Analysis, By Product
11.3 Europe Drugs of Abuse (DOA) Testing Market Size and Forecast, By Sample Type 
11.4 Europe Drugs of Abuse (DOA) Testing Market Size and Forecast, By Application
11.5 Europe Drugs of Abuse (DOA) Testing Market Size and Forecast, By End-User
11.6 Europe Drugs of Abuse (DOA) Testing Market Size and Forecast, By Country
11.6.1 Germany
11.6.2 France
11.6.3 UK
11.6.4. Rest of Europe
12 Asia Pacific Drugs of Abuse (DOA) Testing Market Analysis and Forecast (2022-2027)
12.1 Introduction
12.2 Asia Pacific Drugs of Abuse (DOA) Testing Market Share Analysis, By Product
12.3 Asia Pacific Drugs of Abuse (DOA) Testing Market Size and Forecast, By Sample Type
12.4 Asia Pacific Drugs of Abuse (DOA) Testing Market Size and Forecast, By Application 
12.5 Asia Pacific Drugs of Abuse (DOA) Testing Market Size and Forecast, By End-User
12.6 Asia Pacific Drugs of Abuse (DOA) Testing Market Size and Forecast, By Country
12.6.1 China        
12.6.2 Japan
12.6.3 India
12.6.4. Rest of Asia Pacific
13 Latin America Drugs of Abuse (DOA) Testing Market Analysis and Forecast (2022-2027)
13.1 Introduction
13.2 Latin America Drugs of Abuse (DOA) Testing Market Share Analysis, Product Type
13.3 Latin America Drugs of Abuse (DOA) Testing Market Size and Forecast, By Sample Type
13.4 Latin America Drugs of Abuse (DOA) Testing Market Size and Forecast, By Application 
13.5 Latin America Drugs of Abuse (DOA) Testing Market Size and Forecast, By End-User
13.6 Latin America Drugs of Abuse (DOA) Testing Market Size and Forecast, Country
13.6.1. Brazil
13.6.2. Rest of Latin America
14 Middle East Drugs of Abuse (DOA) Testing Market Analysis and Forecast (2022-2027)
14.1 Introduction
14.2 Middle East Drugs of Abuse (DOA) Testing Market Share Analysis, By Product
14.3 Middle East Drugs of Abuse (DOA) Testing Market Size and Forecast, By Sample Type 
14.4 Middle East Drugs of Abuse (DOA) Testing Market Size and Forecast, By Application 
14.5 Middle East Drugs of Abuse (DOA) Testing Market Size and Forecast, By End-User
14.6 Middle East Drugs of Abuse (DOA) Testing Market Size and Forecast, By Country
14.6.1. Saudi Arabia
14.6.2. UAE
14.6.3. Egypt
14.6.4. Kuwait
14.6.5. South Africa
15 Competitive Analysis
15.1 Competition Dashboard
15.2 Market share Analysis of Top Vendors
15.3 Key Development Strategies
16 Company Profiles
16.1 Takeda Pharmaceutical Company Limited
16.1.1 Overview
16.1.2 Products
16.1.3 Key Financials
16.1.4 Business Segment & Geographic Overview
16.1.5 Key Market Developments
16.1.6 Key Strategies
16.2. F. Hoffmann-La Roche Ltd
16.2.1 Overview
16.2.2 Products
16.2.3 Key Financials
16.2.4 Business Segment & Geographic Overview
16.2.5 Key Market Developments
16.2.6 Key Strategies
16.3. Abbott
16.3.1 Overview
16.3.2 Products
16.3.3 Key Financials
16.3.4 Business Segment & Geographic Overview
16.3.5 Key Market Developments
16.3.6 Key Strategies
16.4 Medtronic
16.4.1 Overview
16.4.2 Products
16.4.3 Key Financials
16.4.4 Business Segment & Geographic Overview
16.4.5 Key Market Developments
16.4.6 Key Strategies
16.5 Johnson & Johnson Services, Inc
16.5.1 Overview
16.5.2 Products
16.5.3 Key Financials
16.5.4 Business Segment & Geographic Overview
16.5.5 Key Market Developments
16.5.6 Key Strategies
16.6 GSK Plc
16.6.1 Overview
16.6.2 Products
16.6.3 Key Financials
16.6.4 Business Segment & Geographic Overview
16.6.5 Key Market Developments
16.6.6 Key Strategies
16.7 Bayer AG
16.7.1 Overview
16.7.2 Products
16.7.3 Key Financials
16.7.4 Business Segment & Geographic Overview
16.7.5 Key Market Developments
16.7.6 Key Strategies        
16.8 Zimmer Biomet
16.8.1 Overview
16.8.2 Products
16.8.3 Key Financials
16.8.4 Business Segment & Geographic Overview
16.8.5 Key Market Developments
16.8.6 Key Strategies
16.9 Stryker Corporation
16.9.1 Overview
16.9.2 Products
16.9.3 Key Financials
16.9.4 Business Segment & Geographic Overview
16.9.5 Key Market Developments
16.9.6 Key Strategies
16.10 Homology Medicines, Inc
16.10.1 Overview
16.10.2 Products
16.10.3 Key Financials
16.10.4 Business Segment & Geographic Overview
16.10.5 Key Market Developments
16.10.6 Key Strategies